ClinicalTrials.gg
TerminatedNCT03430947RadioCoBRIMUpdated Sep 14, 2023

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

A Phase 2 interventional study of Vemurafenib and Cobimetinib in Malignant Melanoma Stage IV, BRAF V600 Mutation and Brain Metastases, sponsored by Technische Universität Dresden. Terminated at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Technische Universität Dresden · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to insufficient recruitment, the clinical trial was terminated prematurely

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies testing vemurafenib in Melanoma — 2 open to participants now, 2 under way, 1 of them phase 3. Vemurafenib · Melanoma.

Enrollment
26th of 56
20 · median 18
Started
2018
with 2 others
Phase 2
21 of 56
none open now
Registered
54th of 56
by date

Among the 56 studies testing vemurafenib in Melanoma, this one is the 26th largest by enrollment, is one of 3 that started in 2018, is one of 21 in phase 2, and was the 54th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 56 studies testing vemurafenib in Melanoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About vemurafenib

Vemurafenib: first FDA approval 2011 (ZELBORAF), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing vemurafenib in Melanoma, or all of them as a file.
02

Study summary

This is a phase II, open label, non-randomised study of vemurafenib and cobimetinib after radiosurgery in adult patients with BRAFV600-mutant melanoma brain metastases. All patients will receive vemurafenib 960 mg twice a day on days 1 - 28 combined with cobimetinib 60 mg once a day on days 1 - 21 of each 28-day treatment cycle until disease progression, drug toxicity or death.

The primary objective of this study is to determine the best overall response rate (BORR) in the brain. The extracranial BORR, intra- and extracranial duration of response, progression-free survival and overall survival, adverse events, quality of life and radiomics features predicting long-term local control of brain metastases and treatment-related toxicity will also be examined.

03

Conditions studied

  • Malignant Melanoma Stage IV
  • BRAF V600 Mutation
  • Brain Metastases

Keywords

  • Stereotactic radiosurgery
  • BRAF inhibitor
  • MEK inhibitor
  • Vemurafenib
  • Cobimetinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Female and male patients ≥ 18 years of age
  • confirmed melanoma (stage IV, per AJCC staging), carrying BRAF V600-mutation
  • Performed SRS 14 ±7 days before baseline using a harmonized protocol in patients with at least one measurable intracranial target lesion for which the following criteria are met:

    • Previously untreated (Lesions in previously irradiated area should not be selected)
    • Largest diameter of ≥ 0.5 but ≤ 4 cm as determined by contrast-enhanced MRI and
    • ≤ 10
  • performance status 0 - 2
  • ≥ 12 weeks
  • Adequate bone marrow function as indicated by the following:

    • ≥ 1500/µL,
    • ≥ 100,000/µL and
    • ≥ 9 g/dL
  • Adequate renal function, as indicated by creatinine ≤ 1.5 x
  • Adequate liver function, as indicated by \< 1.5 x ULN and and ALT \< 3 x ULN (documented liver metastases: AST and ALT \< 5 x ULN)
  • Adequate coagulation within 28 days prior to baseline visit

    • Patients without therapeutic anticoagulation: or aPTT ≤ 1.5 x ULN
    • Patients receiving therapeutic anticoagulation: stable anticoagulation regimen and stable INR
  • Able to swallow pills

Exclusion criteria

Exclusion criteria

  • Symptomatic requiring immediate local interventions such as neurosurgery or radiosurgery
  • (also synchronous with brain metastases)
  • Prior therapy with BRAF or MEK inhibitors within 12 weeks prior to baseline visit (prior therapies for melanoma including chemo-, cytokine-, immuno-, biological and vaccine-therapy will be al-lowed) A period of at least 6 weeks must be observed between the last dose of ipilimumab and the first administration of the study treatments. Prior treatment with anti-programmed cell death (PD)-1 or anti-PD ligand 1 () is allowed.
  • Prior whole brain irradiation (Patients with prior local therapy of brain metas-tases are eligible)
  • Patients receiving therapeutic are not stable on corticoster-oids 2 weeks before SRS
  • Active and uncontrolled infection
  • Known infection or active or infection

    • Active HBV infection (chronic and acute), defined as having a posi-tive hepatitis B surface antigen (HBsAg) test at screening (past or resolved HBV infection, defined as negative HBsAg test and a posi-tive total hepatitis B core antibody test at screening, are eligible)
    • Active HCV infection, defined as positive HCV antibody test and positive HCV RNA test at screening
  • Intracranial radiation therapy within 14 days prior to SRS
  • Extracranial radiation therapy within the last 14 days prior to baseline visit
  • Treatment with strong /5 inhibitors (e.g. ketoconazole) and inducers (e.g. phenytoin, carbamazepine). (anticonvulsant levetiracetam is allowed; patient should be stable on levetiracetam for 2 weeks)
  • Unresolved toxicity of National Cancer Institute Common Terminology Crite-ria for Adverse Events, version 4.0 (NCI v4.0) [NCI, 2009] Grade 2 or higher from previous anti-cancer therapy, except alopecia.
  • Conditions that will interfere significantly with the absorption of drugs (e.g. Colitis ulcerosa)
  • Inability to undergo MRI secondary to:

    • Metal,
    • Claustrophobia, or
    • Gadolinium contrast allergy
  • Previous active within the last 3 years, with the exception of locally curable cancers that have been treated to complete remis-sion or untreated stage I chronic lymphoid leukemia.
  • Unwillingness or inability to comply with study and follow-up procedures
  • Known to any of the of cobimetinib and vemuraf-enib
  • The following foods/supplements are prohibited at least 7 days prior to initia-tion of and during study treatment:

    • St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)
    • Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor)
  • Patient is included in another interventional trial
  • Use of any or non-registered product within 4 weeks prior to baseline visit
  • Woman of childbearing age with the exception they meet at least one of the following criteria:

    • ,
    • Sterilization,
    • Consistently \& correct application of (Pearl Index \< 1%),
    • sexual abstinence, or
    • vasectomy of the partner
  • Pregnant or lactating women
  • History, risk factor or retinal pathology that increases the risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR): evidence of retinal pathology that is considered a risk factor for RVO or CSR, or a history of retinal detachment, central serous chorioretinopathy or reti-nal vein thrombosis. The risk factors for RVO are listed below:

    • Uncontrolled glaucoma with intraocular pressures > 21 mm Hg,
    • Serum cholesterol ≥ Grade 2 (≥ 7.75 mmol/L),
    • Hypertriglyceridemia ≥ Grade 2 (≥ 3.42 mmol/L), Hyperglycemia (fasting) ≥ Grade 2 (≥ 8.9 mmol/L).
  • History of cardiac dysfunction including:

    • Myocardial infarction,
    • Severe/unstable angina pectoris,
    • Symptomatic congestive heart failure ( stage ≥ 2),
    • cerebrovascular accident or within the previous 6 months,
    • History of congenital long syndrome or mean QTcF > 450 msec or uncorrectable electrolyte abnormalities,
    • Hypertension > Grade 2 not controlled by medications
    • (LVEF) \< 50%, or
    • Uncontrolled arrhythmias
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment

    all patients will be treated with Vemurafenib + Cobimetinib

    Drug: Vemurafenib · Drug: Cobimetinib

Interventions

  • Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.

  • Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.

06

What researchers measure

Primary outcomes

  1. Best overall response rate in the brain

    rate of patients with complete response or partial response (intracranial)

    Time frame: 2 years

Secondary outcomes

  1. Extracranial best overall response rate

    rate of patients with complete response or partial response (extracranial)

    Time frame: 2 years

  2. Best overall response rate calculated for the whole body tumor sites

    rate of patients with complete response or partial response

    Time frame: 2 years

  3. Intracranial duration of response

    time from best overall response in the brain to first documentation of intracranial progression

    Time frame: 2 years

  4. Extracranial duration of response

    time from best extracranial overall response to first documentation of extracranial progression

    Time frame: 2 years

  5. Progression-free survival

    time from first dose of study treatment until progression

    Time frame: 2 years

  6. Overall survival

    time from first dose of study treatment until death due to any cause

    Time frame: 2 years

  7. Incidence of adverse events

    Adverse events by type, frequency and severity using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03; number of patients who withdraw from the study due to intolerable adverse events.

    Time frame: 2 years

  8. Radiomics for long-term control of brain metastases

    Radiomics features predictive of long-term local control of brain metastases using Magnetic Resonance Imaging

    Time frame: every 6 weeks up to 2 years

  9. Radiomics for intracranial Treatment-related toxicity

    Radiomics features predicting treatment-related toxicity (e.g. radionecrosis, hemorrhage, edema) using Magnetic Resonance Imaging

    Time frame: every 6 weeks up to 2 years

07

Study locations

3 sites
  • Technische Universität Dresden
    Dresden, 01307, Germany
  • Ruprecht-Karls-University of Heidelberg, Faculty of Medicine
    Heidelberg, 69120, Germany
  • Eberhard Karls University of Tübingen, University Medical Center
    Tuebingen, 72076, Germany
08

References and documents

Individual participant data

Plan to share: Yes — After publication of the primary objective, the data might be provided to interested scientists on request (e.g. for meta-analyses or other scientific research) in an anonymized way within 5 years (according to the General Data Protection Regulation), provided that the sponsor and the coordinating principal investigators have given their prior written consent.

Supporting information: Clinical study report

Time frame: within 5 years

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Feb 2023, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2018
First posted
Feb 13, 2018
StartActual
Jul 1, 2018
Primary completionActual
Feb 10, 2023
CompletionActual
Feb 10, 2023
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03430947
Responsible party
Sponsor
First posted
Feb 13, 2018
Start date
Jul 1, 2018
Primary completion
Feb 10, 2023
Completion
Feb 10, 2023
Last update
Sep 14, 2023

Study contacts

Friedegund Meier, MD
principal investigator · Technische Universität Dresden

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vemurafenib · Cobimetinib

Start the discussion